ESC 365 - Impact of inclisiran on LDL-C over 18 months in patients with ASCVD or risk-equivalent – Results of the Phase 3 ORION-11 trial

ESC Premium Access

Impact of inclisiran on LDL-C over 18 months in patients with ASCVD or risk-equivalent – Results of the Phase 3 ORION-11 trial

Session: Late Breaking Science in Prevention 1

Topic: Drug therapy

Speaker: Professor K. Ray (London, GB)

Event: ESC Congress 2019

Congress Presentation

About the speaker

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

59 presentations

5 followers

3 more presentations in this session

The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry: analyses from over 55,000 cases and 68 countries

Speaker: Doctor A. Vallejo-Vaz (Seville, ES)

New insights into anthropometrics and cardiovascular outcomes in 150 000 adults from 21 countries followed for 9 years: a PURE study

Speaker: Doctor D. Leong (Hamilton, CA)

Cardiovascular outcomes in patients with type 2 diabetes and obesity: Comparison of metabolic surgery versus usual care

Speaker: Doctor A. Aminian (Cleveland, US)

Access the full session

Late Breaking Science in Prevention 1

Speakers: Professor K. Ray, Doctor A. Vallejo-Vaz, Doctor D. Leong, Doctor A. Aminian

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

Related content

ACVC Premium Access

Pulmonary artery catheter use in contemporary cardiac ICUs: the basics.

19 March 2022

ESC Premium Access

IAMI - Panel discussion.

30 August 2021

ESC Premium Access

IAMI - Discussant review.

30 August 2021

ESC 365 is supported by